Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

1. Is the biology right?

• Somatic driver evidence: no · None of NECTIN4, TUBB4B, TUBB1, TACSTD2, TOP1, ERBB2 has somatic-mutation evidence in clear cell adenocarcinoma

  Rule: Open Targets has somatic-mutation evidence for the target in this cancer. Source: Open Targets: NECTIN4 in clear cell adenocarcinoma, 2026-11-11
• Human genetic evidence: no · No germline or somatic evidence for NECTIN4, TUBB4B, TUBB1, TACSTD2, TOP1, ERBB2 in clear cell adenocarcinoma

  Rule: Any germline or somatic human genetic evidence for the target in this cancer, counted apart from animal-model and literature evidence. Source: Open Targets: NECTIN4 in clear cell adenocarcinoma, 2026-11-11
• Pediatric target: yes · ERBB2 on the FDA list

  Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets); membership alone neither requires nor waives a study. Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
• Haematologic cancer: no · Solid tumour

  Rule: From the indication, or the registry conditions when no indication matches. Source: ClinicalTrials.gov NCT06311214, 2026-11-11

  Published context: Likelihood of approval from phase 1: 7.5% haematologic vs 4.6% solid (BIO / Informa / QLS 2021, 2011–2020). Population-level, not a prediction.

• NECTIN4 (via Enfortumab Vedotin): Evidence types in clear cell adenocarcinoma: literature; literature listed separately from human genetics. Datasources: europepmc. · Open Targets: NECTIN4 in clear cell adenocarcinoma
• TUBB4B (via Enfortumab Vedotin): Evidence types in clear cell adenocarcinoma: clinical. Datasources: clinical_precedence. · Open Targets: TUBB4B in clear cell adenocarcinoma
• TUBB1 (via Enfortumab Vedotin): Evidence types in clear cell adenocarcinoma: clinical. Datasources: clinical_precedence. · Open Targets: TUBB1 in clear cell adenocarcinoma
• TACSTD2 (via Sacituzumab Govitecan): Evidence types in clear cell adenocarcinoma: literature; literature listed separately from human genetics. Datasources: europepmc. · Open Targets: TACSTD2 in clear cell adenocarcinoma
• TOP1 (via Sacituzumab Govitecan): Open Targets has no association between TOP1 and clear cell adenocarcinoma. · Open Targets: TOP1 in clear cell adenocarcinoma
• ERBB2 (via Trastuzumab Deruxtecan): Evidence types in clear cell adenocarcinoma: literature; literature listed separately from human genetics. Datasources: europepmc. · Open Targets: ERBB2 in clear cell adenocarcinoma

• Not loaded on this app yet: Normal-tissue expression in vital organs. Source: Human Protein Atlas (ticket 36).
• Not loaded on this app yet: Pan-essential in cell lines. Source: DepMap (ticket 36).
• Not loaded on this app yet: Approved drug on this target. Source: Drugs@FDA (ticket 30).

2. Can the result be trusted?

• Randomised: no · Non-randomised

  Rule: Registry allocation field. Source: ClinicalTrials.gov NCT06311214, 2026-11-11
• Small denominator: no · 500 planned; each patient moves a rate by 100 ÷ 500 = 0.2 points

  Rule: Enrolment under 30; the arithmetic is shown, not a benchmark. Source: ClinicalTrials.gov NCT06311214, 2026-11-11
• Primary endpoint is overall survival: no · Frequency of high protein expression in patients with high ribonucleic acid (RNA) expression of each antibody-drug co…; Objective response rate (treatment cohorts)

  Rule: A registered primary outcome measure names overall survival. Source: ClinicalTrials.gov NCT06311214, 2026-11-11

  Published context: Non-OS primary endpoint: odds ratio 2.79 for a positive phase 3 (Otsuka 2021, 400 phase 3 oncology trials, to 2020). Shown with the next figure: a surrogate is easier to hit, and often a weak guide to survival.

  Published context: 52% of surrogate-to-OS correlations are low (Prasad 2015, published to 2014). Shown with the figure above.
• Results overdue: no · Primary completion expected 2028-03-31; not yet due

  Rule: Primary completion (actual) more than 12 months ago and no results posted to the registry. Source: ClinicalTrials.gov NCT06311214, 2026-11-11

• Not loaded on this app yet: Treated and evaluable counts, assessor, confirmed response, follow-up and data cutoff. Source: Readout extraction (ticket 32).
• Not loaded on this app yet: Primary endpoint changed between registry versions. Source: Registry versions in the store (ticket 32).

3. What must it beat?

• Not loaded on this app yet: Control-arm result and approved therapies for the same segment, with label links. Source: Drugs@FDA, FDA labels and readouts (tickets 30, 32).

4. Too crowded, or too late?

• Stopped on this target: 5 terminated, withdrawn or suspended trials of drugs against NECTIN4. Reasons are quoted as the registry gives them on the target page. · NECTIN4: what already stopped

• Not loaded on this app yet: Programs on the target by phase and months behind the leader. Source: Programs and Drugs@FDA (ticket 33).

5. Can it be approved, and stay approved?

• Single-country: yes · All 29 sites in United States

  Rule: All listed sites are in one country; the share of US sites is shown. Source: ClinicalTrials.gov NCT06311214, 2026-11-11
• EU paediatric investigation plan: yes · EMEA-002299-PIP01-17 (Enfortumab vedotin, Treatment of urothelial carcinoma): W: decision granting a waiver in all age groups for all conditions or indications, 11 Apr 2018; EMA/PE/0000228097 (sacituzumab govitecan, Treatment of endometrial carcinoma): W: decision granting a waiver in all age groups for all conditions or indications, 28 Jan 2025; EMEA-002978-PIP02-24 (trastuzumab deruxtecan, Treatment of all conditions in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)): P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), 5 Dec 2024; EMEA-002299-PIP02-23 (Enfortumab vedotin, Treatment of head and neck epithelial malignant neoplasms): W: decision granting a waiver in all age groups for all conditions or indications, 7 Sept 2023; +5 more

  Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
• EU orphan designation: yes · EU/3/14/1343 withdrawn 15 Oct 2014: Treatment of pancreatic cancer

  Rule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA EU/3/14/1343, 2026-11-11
• Authorised in the EU: yes · Enhertu: authorised since 18 Jan 2021, conditional; Padcev: authorised since 13 Apr 2022; Trodelvy: authorised since 22 Nov 2021

  Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
• FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link

  Rule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
• FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of Enfortumab Vedotin, Sacituzumab Govitecan, Trastuzumab Deruxtecan

  Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
• Registered studies open to children: yes · 4 interventional studies of Enfortumab Vedotin, Sacituzumab Govitecan, Trastuzumab Deruxtecan include patients under 18; 4 are recruiting, not yet recruiting or active

  Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11

• Caveat: Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where the sites are is a fact about the record, not a judgement of its quality.
• Rare pediatric disease voucher: FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. · FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs

• Not loaded on this app yet: Precedent approvals for target, modality and endpoint; accelerated-approval status. Source: Drugs@FDA and FDA accelerated-approval tables (ticket 30).

6. Can the sponsor finish?

• Sponsor: National Cancer Institute (NCI) (academic or other) · ClinicalTrials.gov NCT06311214
• principal investigator: Funda Meric-Bernstam, University of Texas MD Anderson Cancer Center LAO · Person page

• Not loaded on this app yet: Filed cash, quarterly spend and the runway arithmetic. Source: SEC XBRL company facts (ticket 37).
• Not loaded on this app yet: Sponsor's completed vs stopped oncology trials and results-reporting record. Source: Registry, by company (ticket 37).

What public data cannot tell you

Public records cannot show: sales forecasts; a probability of success for this asset; full deal terms and net prices; FDA designations and action dates before approval (shown only as company-reported); clinical holds unless the company disclosed them; manufacturing; patents on unapproved drugs; whether preclinical findings have been replicated.